BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 9362424)

  • 21. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
    Myoui A; Nishimura R; Williams PJ; Hiraga T; Tamura D; Michigami T; Mundy GR; Yoneda T
    Cancer Res; 2003 Aug; 63(16):5028-33. PubMed ID: 12941830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.
    Pollari S; Käkönen RS; Mohammad KS; Rissanen JP; Halleen JM; Wärri A; Nissinen L; Pihlavisto M; Marjamäki A; Perälä M; Guise TA; Kallioniemi O; Käkönen SM
    Mol Cancer Res; 2012 May; 10(5):597-604. PubMed ID: 22522458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
    Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
    J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
    Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
    Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
    Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
    Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
    Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
    Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
    Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
    Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer.
    Johnson RW; Merkel AR; Page JM; Ruppender NS; Guelcher SA; Sterling JA
    Clin Exp Metastasis; 2014 Dec; 31(8):945-59. PubMed ID: 25359619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis.
    Wright LE; Frye JB; Lukefahr AL; Timmermann BN; Mohammad KS; Guise TA; Funk JL
    J Nat Prod; 2013 Mar; 76(3):316-21. PubMed ID: 23145932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.
    Bendre MS; Gaddy-Kurten D; Mon-Foote T; Akel NS; Skinner RA; Nicholas RW; Suva LJ
    Cancer Res; 2002 Oct; 62(19):5571-9. PubMed ID: 12359770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
    Saito H; Tsunenari T; Onuma E; Sato K; Ogata E; Yamada-Okabe H
    Anticancer Res; 2005; 25(6B):3817-23. PubMed ID: 16309168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases.
    Ponnapakkam T; Anbalagan M; Stratford RE; Rowan BG; Gensure RC
    Anticancer Drugs; 2021 Apr; 32(4):365-375. PubMed ID: 33595947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.
    Page JM; Merkel AR; Ruppender NS; Guo R; Dadwal UC; Cannonier S; Basu S; Guelcher SA; Sterling JA
    Biomaterials; 2015 Sep; 64():33-44. PubMed ID: 26115412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.
    Dunn LK; Mohammad KS; Fournier PG; McKenna CR; Davis HW; Niewolna M; Peng XH; Chirgwin JM; Guise TA
    PLoS One; 2009 Sep; 4(9):e6896. PubMed ID: 19727403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
    Guise TA; Chirgwin JM
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.